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Background. Optimization of combination antiretroviral therapy (cART) can impact the human immunodeficiency virus 
(HIV) reservoir. We evaluated the effect on the HIV reservoir in peripheral blood and ileum biopsies in patients switching from 
boosted protease inhibitor (PI/r)–based therapy to dolutegravir (DTG)–based therapy.
Methods. Impact of Integrase-inhibitor DOlutegravir On the viral Reservoir (INDOOR) is a phase 4 open-label clinical trial 
that randomly included 42 HIV type 1–infected individuals on effective cART: 20 who switched from PI/r-based to DTG-based 
cART (switch group), and 22 who remained in PI/r-based regimens (control group). We analyzed blood and ileum biopsies to quan-
tify episomal, total, and integrated HIV DNA, cell-associated HIV RNA, residual plasma viremia, T-cell subsets, cell activation, and 
inflammation markers.
Results. There were no related adverse events or treatment discontinuations due to drug intolerance. The HIV reservoir was con-
sistently larger in ileal than in peripheral CD4+ T cells in both groups (P < .01). Residual viremia in plasma decreased in the switch 
group (P =  .03). However, we did not observe significant longitudinal changes in low-level viral replication, total and integrated 
HIV reservoir, HIV transcription, T-cell maturation subsets, immunoactivation markers, inflammatory soluble proteins, or cellular 
markers of latently infected cells.
Conclusions. The INDOOR study is the first evaluation of changes in HIV reservoir size in ileum biopsies and in peripheral 
blood in individuals switched from PI/r- to DTG-based cART. Although this switch was safe and well tolerated, it had no impact on 
a large array of immunological and inflammatory markers or on HIV reservoir markers in peripheral or in ileal CD4+ T cells.
clinical Trials Registration. EudraCT 2014-004331-39.
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Effective combination antiretroviral therapy (cART) sup-
presses viral replication to undetectable levels as assessed using 
standard clinical assays. It also reduces morbidity and mor-
tality and improves the quality of life of human immunodefi-
ciency virus (HIV)–infected individuals [1, 2]. Around 30% of 
infected individuals are currently treated using cART regimens 
based on boosted protease inhibitors (PI/r). However, PIs have 
been associated with adverse events such as long-term toxicity, 
interactions with other drugs, and an increased risk of cardi-
ovascular disease [3]. Therefore, in clinical practice, switching 
to an integrase strand transfer inhibitor (INSTI) has become 
a common strategy to prevent long-term metabolic disorders 
and to manage drug–drug interactions [4, 5]. Furthermore, 
some studies report a decrease in the viral reservoir and host 
immune activation after switching the third drug to an INSTI 
[6, 7]. Several mechanisms contribute to the maintenance of 
the viral reservoir, including homeostatic dynamics within the 
CD4+ T-cell pool [8, 9], anatomical sanctuary sites [10, 11], 
and low-level viral replication [12–14], which leads to the de-
tection of residual plasma viremia in antiretroviral therapy 
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(ART)–suppressed individuals. However, the origin of residual 
virus production during ART remains unknown.
Raltegravir (RAL) is the only INSTI that has been investi-
gated in cART-switching clinical trials evaluating the effects of 
therapy on the HIV reservoir [6, 15, 16]. However, the effect 
of switching to RAL-based regimens remains unclear. Two 
studies have shown no effect on total or episomal HIV DNA 
[15, 16], while another showed a decrease in the HIV reservoir 
size after 48 weeks of switching to a RAL-based regimen [6]. 
Furthermore, the effect of switching to integrase inhibitors on 
the HIV reservoir has been evaluated in peripheral blood [6, 15, 
16], but not in lymphoid tissue. Gut tissue is a key site for the 
HIV reservoir [17], although sampling remains difficult [18].
Dolutegravir (DTG) was superior to RAL with respect to 
virological suppression (<50 copies/mL) in treatment-experi-
enced individuals who were INSTI-naive [19]. A recent study 
showed that individuals receiving RAL or DTG have compa-
rable HIV DNA in gut-associated lymphoid tissue (GALT) 
[20]. However, whether its role in the dynamics of the HIV 
type 1 (HIV-1) reservoir is similar to that of RAL is unknown. 
Therefore, we compared the effect of switching to DTG-based 
cART or maintaining PI/r-based cART on the HIV reservoir, in 
both peripheral blood, and ileum biopsies from HIV-infected, 
ART-suppressed individuals.
MATERIALS AND METHODS
Study Design
Impact of Integrase-inhibitor DOlutegravir On the viral Reservoir 
(INDOOR) (EudraCT identifier 2014-004331-39) was a phase 4, 
randomized, open-label clinical trial, conducted from June 2015 to 
November 2016 at Vall d’Hebron University Hospital (Barcelona, 
Spain). We enrolled HIV-1–infected adults with HIV RNA <50 
copies/mL for at least 1 year on a stable regimen containing a PI/r 
plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) for at 
least 3 months and CD4 T-cell count >200 cells/μL.
Selected participants were randomly assigned (1:1) to switch 
to DTG plus 2 NRTIs or to continue the same regimen contain-
ing a PI/r plus 2 NRTIs (Figure 1). A blocked randomization 
method was used by creating random block sizes and blinding 
the investigator to the size of each block.
All of the individuals included in the study were asked to par-
ticipate in a substudy to obtain endoscopic ileum biopsies.
The local ethics committee approved the protocol, and the 
study was performed in accordance with the principles of the 
Declaration of Helsinki. All participants provided written 
informed consent before inclusion.
Procedures
We collected blood samples at weeks 0, 1, 2, 4, 12, and 24 from 
all participants, and ileum samples at weeks 0 and 24 from those 
included in the GALT biopsy substudy. Procedures are described 
in Supplementary Materials and in Supplementary Figure 1.
Statistical Analyses
Statistical significance was set at 5% for all the tests, and sig-
nificant P values were adjusted using the false discovery rate 
method for multiple comparisons. The analyses were performed 
using R (version 3.0.2) and GraphPad (version 5.01) software, 
and are described in Supplementary Materials.
RESULTS
Cohort Characteristics and Clinical Outcome
A total of 49 participants were screened; of these, 44 were 
randomized to switch to DTG (n  =  22, switch arm) or to 
continue the same PI/r-based cART regimen (n  =  22, con-
trol arm). Two participants discontinued the study protocol: 
1 had a previous psychiatric history and experienced a psy-
chotic decompensation; the other had a baseline CD4+ count 
<200 cells/μL at the first visit. One subject in the control 
group with suppressed viremia at week 12 did not attend at 
week 24. The remaining randomized individuals completed 
the study protocol (Figure 1).
The baseline characteristics are summarized in Table 1. The 
number of participants with heterosexual HIV infection was 
significantly higher in the switching arm (P = .02). Otherwise, 
treatment arms were well balanced for demographic and 
clinical data.
Ninety percent (18/20) of participants in the DTG arm and 
76.2% (16/21) in the control group maintained viral suppres-
sion at week 24. At the safety visit, 4 weeks after completing 
the 24-week study duration, 100% (20/20) of subjects in the 
switch group had viral load <50 copies/mL, whereas 3 individ-
uals (14.3%) receiving a PI-based regimen had detectable vire-
mia of 50–200 copies/mL. Self-reported adherence was >95%. 
No drug-related adverse events during follow-up or discon-
tinuations due to drug intolerance were reported. Individuals 
switching to DTG showed an improved lipid profile. Total 
cholesterol, low-density lipoprotein cholesterol, triglycerides, 
and the cholesterol/high-density lipoprotein cholesterol ratio 
changed a median of –27 (interquartile range [IQR], –39 to 
–13.5) mg/dL, –21.3 (IQR, –28.3 to 4.3) mg/dL, –37.5 (IQR, 
–84.8 to 7) mg/dL, and –0.32 (IQR, –0.57 to 0.05), respectively 
(Supplementary Figure 2).
Colonoscopy Findings
Thirty-three participants participated in the ileum biopsy 
substudy: 13 from the switch arm and 20 from the control 
group (Supplementary Table 1). Of these, 11 and 19, respec-
tively, had paired biopsies. Individuals in the switch arm of 
the substudy were younger (48 vs 54 years; P = .02), and time 
since HIV diagnosis was shorter than in the control group (15 
[IQR, 10.5–21] years vs 20.5 [IQR, 15.25–26.5] years; P = .04). 
Colonoscopy was abnormal in 9 (27.3%) subjects. The main 
findings were tubular adenoma with low-grade dysplasia 
(n = 5), tubular adenoma with high-grade dysplasia (n = 1), 
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hyperplastic polyps (n  =  2), and squamous cell carcinoma 
(n = 1). No participant had gastrointestinal complaints before 
colonoscopy.
2-LTR Dynamics in Peripheral CD4+ T Cells
To determine the effect of switching, we analyzed changes in 
low-level viral replication by quantification of 2-LTR circles in 
peripheral CD4+ T cells. At baseline, we detected episomal HIV 
DNA at all the time points in 14 participants (33%) and at ≥1 
time point in 41 participants (98%), with a median level of 6.20 
(IQR, 0.00–17.35) 2-LTR copies per million CD4+ T cells in the 
switch group and 2.35 (IQR, 0.00–7.65) in the control group. 
We observed no statistically significant longitudinal changes 
in either of the groups or between the groups during the study 
(Figure 2A). These results confirm the persistence of low-level 
viral replication during PI/r-based regimens that is not affected 
by switching to DTG-based ART.
Residual Viremia in Plasma
To determine the effect of switching on residual plasma viremia, 
we quantified the HIV RNA copies/mL of plasma by detecting 
ultrasensitive viral load. Residual plasma viremia was detected in 
95% of the participants with a median level of 7.7 (IQR, 2.5–19.2) 
HIV RNA copies/mL plasma in the switch group and 3.8 (IQR, 
1.0–8.6) in the control group. Interestingly, we observed a de-
crease in residual viremia in the switch group at week 12. This 
became significant at week 24 (P = .03; Figure 2B); however, the 
significance was lost after correction for multiple comparisons. 
Although we observed no significant differences between groups 
over time, there was a trend between groups at baseline, namely, 
a slightly higher residual viral load in the switch arm (P = .07). 
Nonetheless, this trend was not related to time to suppression or 
any other clinical parameter evaluated in the study. These find-
ings suggest that switching may decrease residual plasma viremia 
in individuals who have a relatively higher residual viral load.
A
B
Study flow diagram
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- Received allocated intervention (n=22)
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- Received allocated intervention (n=22)
Allocation
Discontinued intervention at week 0 (n=2)
- Subject with CD4+ T-cell count <200 cells/µL
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Follow-up
Analyzed (n=20) Analyzed (n=22)
Analysis
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(at least 3 months) Control arm: PI/r + 2 NRTIs
42214210
Time (weeks)
Switch arm: DTG + 2 NRTIs
Figure 1. Trial design. A, Consolidated Standards of Reporting Trials (CONSORT) flow diagram for the trial showing the enrollment of 44 subjects who were randomized 
to the switch or control groups. According to our experience, in order to assess the impact on cryptic human immunodeficiency virus (HIV) replication, it is important to 
evaluate changes affecting 2-LTR, which, owing to their ephemeral nature, can only be detected in recently infected cells, and changes affecting HIV RNA expression during 
the first 4 weeks following switching from boosted protease inhibitor to dolutegravir (DTG). Consequently, sample size was estimated on the assumption that switching to 
DTG is associated with an increase of >30% in the proportion of patients with detectable episomal HIV DNA (2-LTR) in peripheral blood mononuclear cells at study week 4 
[13]. Mathematical modeling of data obtained from this study suggests that the transient increase in measured 2-LTR concentration is consistent with the blocking effect 
of the integrase inhibitor on de novo infection [27]. Taking into account all of the above, a total of 40 individuals was needed, 20 in each group. We recruited 44 subjects to 
accommodate for dropouts and a 10% loss to follow-up. B, Study design. Abbreviations: NRTI, nucleoside reverse transcriptase inhibitor; PI/r, boosted protease inhibitor.
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Reservoir Quantification in Ileal and Peripheral CD4+ T Cells
To provide further insights into the effect of switching on the 
size of the HIV reservoir, we quantified total HIV DNA in ileal 
CD4+ T cells and total and integrated HIV DNA and unspliced 
cell-associated HIV RNA in peripheral CD4+ T cells.
At baseline, using cell lysates, we detected total HIV DNA 
in 100% of samples, with a median of 989 (IQR, 472–1210) 
total HIV DNA copies/million peripheral CD4+ T cells in the 
switch group, and 1099 (IQR, 554–1624) in the control group 
(Figure 2C). Using DNA extraction, we detected total HIV 
DNA in 41 participants (98%) and observed a strong correla-
tion between quantification using lysates and extracted DNA at 
week 0 (n = 41; P < .0001; ρ = 0.89; Supplementary Figure 3A). 
We detected integrated HIV DNA levels in peripheral CD4+ T 
cells in 41 participants (98%), with a median level of 634 (IQR, 
415–1199) HIV DNA integrated copies/million CD4+ T cells in 
the switch group, and 725 (IQR, 235–1023) in the control group 
(Figure 2D). Moreover, we detected unspliced HIV RNA in 34 
participants (81%), with a median level of 2.5 (IQR, 0.0–4.8) 
unspliced HIV RNA/million CD4+ T cells in the switch group 
and 2.3 (IQR, 0.0–4.3) in the control group (Figure 2E). We also 
observed strong correlations between total and integrated HIV 
DNA (P < .0001; ρ = 0.88; Supplementary Figure 3B) and total 
or integrated HIV DNA and unspliced HIV RNA (P  =  .004, 
ρ = 0.58; P = .007, ρ = 0.55, respectively; Supplementary Figure 
3C and 3D). However, we observed no statistically significant 
longitudinal changes in any of these reservoir markers within 
or between the groups.
We detected total HIV DNA in 100% of the ileum biopsies. 
We found 2151 (IQR, 1564–5615) total HIV DNA copies/mil-
lion CD4+ T cells in the switch group and 3372 (IQR,  2234–
4806) in the control group at week 0 (Figure 3A), showing 
higher levels of total HIV DNA in ileal than in peripheral CD4+ 
T cells in both the switch and control groups (P < .001). We also 
observed a direct trend between the size of the HIV reservoir in 
CD4+ T cells from the ileum and from peripheral blood at week 
0 (n = 33; P =  .07; ρ = 0.32; Supplementary Figure 3E). As in 
peripheral blood, we did not detect longitudinal changes in the 
size of the HIV reservoir in ileum samples.
These results indicate that the HIV reservoir is larger in the 
ileum than in peripheral blood and that there is a strong pos-
itive correlation between total and integrated HIV DNA and 
between HIV DNA and unspliced HIV RNA.
Activation Markers in Ileum Biopsies and in Peripheral Blood
To determine whether switching to DTG-based therapy 
decreases cell activation, we compared the percentage of 
CD38+HLA-DR+ in CD4+ and in CD8+ T cells in both groups 
in ileum biopsies and in peripheral blood. We observed a 
higher percentage of activated CD4+ (14.5%) and CD8+ T 
cells (16.7%) from ileum biopsies than in cells from peripheral 
blood (1.6% and 1.7%, respectively; P  <  .001; Figure 3B and 
Table 1. Baseline Characteristics
  INDOOR Trial
Characteristic All (N = 42) Switch Arm (n = 20) Control Arm (n = 22) P Value
Age, y, median (IQR) 49 (46–54) 49 (45–53) 53 (46–55) .21
Sex     
 Female 12 (29) 8 (40) 4 (18) .17
 Male 30 (71) 12 (60) 18 (82)
HIV infection route     
 IDU 23 (55) 10 (50) 13 (58) .02
 MSM 3 (7) 0 3 (14)
 Heterosexual 13 (31) 10 (50) 3 (14)
 Unknown 3 (7) 0 3 (14)
Time since diagnosis of HIV, y, median (IQR) 17.5 (11.8–25) 16 (11–23.8) 20 (13.8–25.3) .19
Time since initiation of cART, y, median (IQR) 12 (6–18.3) 12 (5.3–18) 12 (7.5–19) .65
Time on current PI-based cART regimen, y, median (IQR) 4 (3–7) 4.5 (3–7) 4 (2.8–8.5) .96
Time with suppressed VL, median (IQR) 4 (3–8.3) 3 (2.3–7.3) 5.5 (3–9) .23
Nadir CD4+ count, cells/μL, median (IQR) 199 (83–297) 204 (95–259) 197 (89–289) .85
Absolute CD4+ count, cells/μL, median (IQR) 620 (495–920) 610 (470–760) 625 (503–1235) .11
% CD4+ T cells, median (IQR) 33.2 (28.4–39.2) 31.8 (28.3–35.2) 35.6 (29.5–42.1) .16
Absolute CD8+ count, cells/μL, median (IQR) 810 (605–1050) 670 (605–890) 905 (680–1215) .19
% CD8+ T cells, median (IQR) 40.9 (34.8–47.8) 40.4 (32.2–47.9) 41.7 (35.8–47.7) .51
CD4:CD8 ratio, median (IQR) 0.8 (0.6–1.1) 0.8 (0.6–1.0) 0.9 (0.7–1.1) .68
HIV-1 RNA copies/mL plasma, median (IQR) <50 <50 <50 .50
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: cART, combination antiretroviral therapy; HIV, human immunodeficiency virus; IDU, injection drug use; IQR, interquartile range; INDOOR, impact of Integrase-inhibitor 
DOlutegravir On the viral Reservoir; MSM, men who have sex with men; PI, protease inhibitor; VL, viral load.
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3C). However, we only observed an increase in the percentage 
of CD8+CD38+HLA-DR+ cells in the control group over time 
(P  =  .02; Figure 3C). We did not observe changes between 
groups. These results confirmed that there are more activated 
cells in tissue than in peripheral blood and that switching did 
not reduce this activation.
Dynamics of Cellular Subsets, Activation, and Reservoir Surrogate 
Markers in Peripheral Blood
No significant differences were observed for frequency of CD4+ 
and CD8+ T cells and the CD4/CD8 ratio between the groups at 
any time point. Furthermore, no significant longitudinal differ-
ences were observed in either group (Supplementary Table 2).
In CD4+ T cells, we observed a decrease in naive and terminal 
effector CD45RA+ cells during week 0–24 in the control group, 
an increase in effector cells during weeks 0–12 in the control 
group, and an increase in the switch group during weeks 0–24. 
However, no differences between groups were observed for any 
maturation subset at any time point (Figure 4A). Activation 
levels decreased over time in both groups (weeks 0–12 and 
weeks 12–24) without intergroup differences (Figure 4B and 
Supplementary Table 2). We found the same behavior in both 
groups when we analyzed LAG-3 and TIM-3 expression in 
CD4+ T cells (Figure 4C and 4D). CD2bright showed a significant 
decrease (weeks 0–24) in the switch group, although no signif-
icant differences between groups were observed (Figure 4E). 
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Figure 2. Analysis of human immunodeficiency virus (HIV) reservoir dynamics in peripheral CD4+ T cells. A, 2-LTR circles. B, Ultrasensitive viral load in plasma. C, Total HIV 
DNA. D, Integrated HIV DNA. E, Cell-associated unspliced HIV RNA. The switch group is shown in blue and the control group in gray. Solid black dots represent determinations 
below the limit of quantification. Abbreviations: caHIV, cell-associated HIV; LOQ, limit of quantification.
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Finally, the expression of CD32 and PD-1 in CD4+ T cells was 
stable over time and similar between groups (Figure 4F and 4G 
and Supplementary Table 2).
Maturation in CD8+ T cells showed significant increases in 
central memory cells (weeks 12–24), naive cells (weeks 0–12), 
and effector cells (weeks 0–12) in the control group, while 
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Figure 3. Human immunodeficiency virus (HIV) reservoir dynamics and T-cell activation in ileum biopsies. A, Total HIV DNA in ileal vs peripheral CD4+ T cells. B and C, 
Comparison of CD4+ and CD8+ CD38+HLA-DR+ T cells in ileum biopsies and in peripheral blood mononuclear cells quantified by FACSAria II and longitudinal follow-up of CD4+ 
and CD8+ CD38+HLA-DR+ T cells in the switch and the control groups. The switch group is shown in blue and the control group in gray. Abbreviation: PBMC, peripheral blood 
mononuclear cell.
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only the latter cell subset increased in the switch group (weeks 
0–24). Again, no differences between groups were observed 
for any maturation subset at any time point (Figure 4H). The 
percentage of activated CD8 cells decreased similarly in both 
groups (Figure 4I). No major changes were noticed for other 
markers in CD8+ T cells between the groups (Supplementary 
Table 2).
Inflammatory Markers in Plasma
We did not observe any differences in interleukin 6, C-reactive 
protein, TNF-related apoptosis-inducing ligand (TRAIL), or 
interferon gamma-induced protein 10 (IP-10) levels over time 
or between groups. However, we observed a significant decrease 
in soluble CD14 (sCD14) levels (weeks 0–12 and weeks 0–24) 
in the switch group that was not significant between groups 
(Supplementary Table 3).
DISCUSSION
This is the first study to compare the dynamics of HIV-1 res-
ervoirs after the switch from PI/r- to DTG-based regimens in 
peripheral blood and in ileum biopsies from cART-suppressed 
individuals. Our results showed that switching to DTG-based 
therapy is not associated with changes in low-level viral replica-
tion, as no fluctuation in the level of episomal HIV DNA (2-LTR) 
was observed. In addition, there was no decay in other HIV 
reservoir markers, such as total and integrated HIV DNA, and 
unspliced HIV RNA, either in peripheral or in ileal CD4+ T cells 
after 24 weeks. Interestingly, we detected a significant decrease in 
residual plasma viremia and sCD14 after 24 weeks of switching to 
DTG-based therapy, although significance is lost after correction 
for multiple comparisons. Furthermore, we did not detect signif-
icant changes in T-cell activation or other plasma inflammation 
markers. Therefore, switching to DTG in individuals on suppres-
sive PI/r-based regimens may reduce residual plasma viremia 
and sCD14, although it did not significantly alter the size of the 
viral reservoir, low-level viral replication, or immune activation.
These findings are consistent with those of previous studies 
comparing switching to RAL [15, 16] or intensification of 
treatment with DTG [21], in which there were no significant 
changes in HIV reservoir size or in low-level viral replication 
Figure 4. Analysis of CD4+ and CD8+ T-cell subsets and activation markers. A, Median CD4+ T-cell values for the frequency of the maturation subsets (naive, central 
memory, effector memory, transitional memory, and effector memory RA+) in the control and switch groups at 3 different time points (weeks 0, 12, and 24). Maturation 
stages were defined based on the combination of CD45RA, CD197 (CCR7), and CD27, as described in “Materials and Methods.” B–G, Dynamics of CD4+ T-cell activation 
(percentage CD4+HLA-DR+CD38+ cells), exhaustion (percentage CD4+PD-1+), and potential HIV reservoir markers (percentage of CD4+LAG-3+, CD4+TIM-3+, CD4+CD2bright, and 
CD4+CD32bright) in both groups. H, Median CD8+ T-cell values for the frequency of the maturation subsets (naive, central memory, effector memory, transitional memory, and 
effector memory RA+) in the control and switch groups at 3 different time points (weeks 0, 12, and 24). I, Dynamics of CD8+ T-cell activation (percentage CD8+HLA-DR+CD38+ 
cells) in both groups. The switch group is shown in blue and the control group in gray.
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associated with the intervention. However, our results contrast 
with those of the RAltegravir Switch for Toxicity or Adverse 
Events (RASTA) study [6], which showed a significant decrease 
in HIV reservoir size, measured by total HIV DNA in peripheral 
blood after 48 weeks of switching successful therapy to RAL-
based regimens. HIV reservoir size can decrease during the first 
3 years after initiation of cART [22]. Nonetheless, in the RASTA 
study, the switch group comprised individuals who had been 
ART suppressed for <3 years, whereas subjects from the control 
group had been suppressed for >5 years (P = .02), and effective 
viral suppression was considered a viral load <200 copies/mL. 
In contrast, in our study, we considered effective suppression a 
viral load <50 copies/mL, and the INDOOR participants were 
suppressed for >3 years in both groups. Moreover, we followed 
participants until week 24 after switching to DTG, while RASTA 
follow-up was until week 48, with no significant decreases in 
the HIV reservoir at week 24. Beyond cohort differences, the 
discrepancy between the 2 studies may also be explained by dif-
ferences between RAL and DTG pharmacokinetics and tissue 
penetration. Previous studies estimated concentrations of DTG 
in rectal tissue to be 17% of those in plasma [23], as compared 
with RAL, where concentrations in the gastrointestinal tract 
can be >600 times higher than in plasma [24]. Moreover, Weber 
et  al recently showed that individuals receiving RAL or DTG 
have comparable HIV DNA in GALT [20]. Nevertheless, the 
lack of effect of DTG on episomal markers of viral replication 
in our switch and in a recent intensification study [21] contrasts 
with previous reports on intensification of RAL [13, 14]. It is 
debatable whether transiently produced 2-LTR circles are the 
result of ongoing cycles of viral replication or merely persistent 
viral release from productively infected cells. However, math-
ematical modeling of the data suggests that the transient dy-
namics of 2-LTR after intensification with integrase inhibitors 
would be more compatible with the former hypothesis [25–27]. 
Consequently, we might suspect a differential effect of DTG 
on the dynamics of 2-LTR circles, although we verified the ab-
sence of such differences in vitro (Supplementary Figure 4). 
Alternatively, lower levels of residual viral replication in recent 
studies might be explained by the inclusion of individuals with 
a more favorable profile, including a higher CD4+ T-cell nadir, 
probably due to earlier initiation of treatment. Therefore, fur-
ther investigation comparing switching to RAL and to DTG in 
samples from peripheral blood and different tissues and meas-
urement of drug concentrations and residual viral replication 
in tissues would be needed to better understand differences in 
the pharmacological effect of RAL and DTG switching inter-
ventions in vivo.
Nevertheless, as previously reported, our results revealed a 
larger HIV reservoir and greater activation in CD4+ T cells from 
ileum biopsies than in those from peripheral blood [28]. We 
also found a strong correlation between markers of persistence 
of HIV [29].
Furthermore, the lack of change in cell activation and plasma 
inflammation markers is consistent with the lack of effect on 
HIV reservoir size in both the ileum and blood and with the 
absence of change in low-level viral replication in blood. Thus, 
our data suggest that switching to a DTG-based regimen from 
a PI/r-based regimen does not reduce immune activation or in-
flammation markers in blood and does not improve standard 
cART beyond avoiding long-term metabolic disorders and 
managing drug–drug interactions [4]. In line with previous 
studies, switching to DTG in the INDOOR study did not jeop-
ardize virological efficacy [30–32], but improved triglycerides 
and the remaining proatherogenic lipid fractions [30–32].
The strengths of this study lie in its prospective design with 
randomization, switch-control (1:1), predefined frequent anal-
yses of 2-LTR changes within the first 4 weeks, and the analysis 
of ileum biopsies. Our study is also subject to limitations. First, 
it is difficult to exclude a small effect on 2-LTR circles owing 
to the number of undetectable determinations. Second, we 
observed baseline differences between groups in the infection 
route and a trend toward higher residual plasma viremia in the 
switch group. However, we corrected for baseline differences in 
the statistical analysis and did not observe any association be-
tween these variables and the overall results. Finally, sampling 
limitations prevented us from measuring 2-LTR in the ileum 
biopsies. Consequently, an effect on low-level viral replication 
in lymphoid tissue cannot be excluded.
In conclusion, we found that switching from PI/r- to DTG-
based therapy maintains viral suppression, improves lipid pro-
file, and may reduce HIV residual plasma viremia. However, we 
observed no evidence of an increase in the level of 2-LTR cir-
cles in peripheral blood CD4+ T cells or a decrease in total HIV 
reservoir size in either ileal or peripheral CD4+ T cells after 24 
weeks of treatment in HIV-infected, ART-suppressed individu-
als. Furthermore, switching to DTG did not affect T-cell activa-
tion or inflammation markers.
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